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In 2015, there were an estimated 10.4 million new cases of tuberculosis (TB) globally,
making it one of the leading causes of death due to an infectious disease. TB is caused by
members of theMycobacterium tuberculosis complex (MTBC), with human disease resulting
from infection by M. tuberculosis sensu stricto and M. africanum. Recent progress in geno-
typing techniques, in particular the increasing availability of whole genome sequence
data, has revealed previously under appreciated levels of genetic diversity within the
MTBC. Several studies have shown that this genetic diversity may translate into differ-
ences in TB transmission, clinical manifestations of disease, and host immune responses.
This suggests the existence of MTBC genotype-dependent host–pathogen interactions
which may influence the outcome of infection and progression of disease. In this review,
we highlight the studies demonstrating differences in innate and adaptive immunological
outcomes consequent on MTBC genetic diversity, and discuss how these differences in
immune response might influence the development of TB vaccines, diagnostics and new
therapies.
Keywords: Adaptive and innate immunity  Genetic diversity  Host response  Mycobacterium
tuberculosis complex  Translational implications
Introduction
Tuberculosis (TB), caused bymembers of theMycobacterium tuber-
culosis complex (MTBC), is a chronic disease that affects humans
and animals [1]. The MTBC includes strictly human pathogens M.
tuberculosis sensu stricto (Mtb) andM. africanum [2] that are clas-
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sified into different lineages according to their phylogeographic
structure, which is hypothesized to reflect adaptation to the human
populations in which they cause disease. Animal-adapted MTBC
strains include M. bovis, a pathogen of cattle and badgers [3]; M.
microti, found in rodents [4]; M. pinnipedii infects sea lions [5];
M. caprae in goats [6]; the recently described M. orygis which
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Figure 1. Schematic diagram illustrating the evolutionary relationship between selected members of the MTBC [1, 84, 111, 112]. Human-adapted
and animal-adapted members of the MTBC can be classified according to the absence or presence of deletions known as regions of difference
(RD), which were originally defined by [1] Grey boxes indicate the specific deletion event that has occurred on the branches leading to a lineage.
Human-adapted strains of the MTBC are grouped into 7 lineages and are associated with specific geographic regions. In themain text of the article,
we refer to these lineages using the numerical nomenclature; however, the alternative nomenclature reflecting the geographic region wherein
strains are prevalent is indicated below the numerical name. The presence or absence of the TbD1 regions discriminates modern (highlighted in a
pink box) and ancient human-adapted MTBC strains. Animal-adapted members of the MTBC, together with the host that is infected by that strain,
are indicated on the figure.
infects wild buck [7]; M. mungi, which was isolated in mongoose
populations [8] and M. suricattae in meerkats (Fig. 1). Zoonotic
transmission of MTBC to humans mainly involves M. bovis. Other
animal adapted members have rarely been isolated from humans,
thereby making the humans the only significant natural reservoir
responsible for the global TB burden.
With the development of genotyping techniques a phylogeo-
graphic genetic structure for the MTBC began to emerge [1]
(Table 1). Large insertions and deletions within the genome,
referred to as large sequence polymorphisms (LSPs), were ini-
tially used to characterize the evolution and phylogeography of
the MTBC [1]. The association of lineages with specific host pop-
ulations led to a nomenclature for MTBC lineages which mir-
rors geographic regions where lineages predominate [9] (Fig. 1).
MTBC phylogenies subsequently constructed using whole genome
sequence (WGS) data were congruent with those generated using
LSPs [10], and are used in this review. Human-adapted MTBC
strains are grouped into seven lineages classified as “ancient”
(lineages 1, 5, 6, and 7) or “modern” (2, 3, and 4) according
to the presence or absence of the tuberculosis-specific deletion
(TbD1) region (Fig. 1). While modern MTBC lineages (i.e. lineage
2 and 4) have spread globally, most ancient lineages (i.e. lineage
5 and 6 (West Africa) and lineage 7 (Ethiopia)) remain geograph-
ically restricted to specific regions/countries where they cause
disease [11]. Moreover, WGS data has been used to demonstrate
significant intra-lineage diversity in lineage 2 [12] and lineage
4 groups [13]. In a recent study, Stucki et al. show that certain
lineage 4 sublineages are more geographically distributed than
others [13].
Differences in virulence between MTBC strains were reported
as early as the 1960s, with the observation that MTBC isolated
in India were attenuated in the guinea pig model when com-
pared with those isolated in the UK [14]. When genotyping tech-
niques became available in the 1990s, outbreaks caused by spe-
cific MTBC strains could be delineated and these strains have been
characterized in a range of models [15]. Two of the most highly
chacterized outbreak strains are Mtb CDC1551and HN878. The
CDC1551 strain, a member of lineage 4, was responsible for a TB
outbreak, that exhibited an unusually high rate of tuberculin skin
test (TST) conversion in contacts [16]. Subsequently it was shown
that CDC1551 induced high levels of IL-12 and IFN-γ in mice,
which may explain the observation of high levels of TST conver-
sion [17]. The HN878 Mtb, a lineage 2 strain, was implicated in
multiple outbreaks in Houston, Texas, USA, and was shown to be
C© 2017 The Authors. European Journal of Immunology published by
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Table 1. Common genotyping techniques for MTBC [111, 113, 114]
Technique Principle Advantages Disadvantages
Spoligotyping • Polymorphism at a direct repeat
(DR) locus is used to discriminate
strains. The locus is in fact made
up of clustered regularly
interspaced short palindromic
repeats (CRISPRs), and in other
bacteria are associated with
bacterial immunity to foreign
DNA.
• PCR and reverse hybridization is
applied to detect the presence or
absence of 35 – 41bp “spacer”
regions, which occur between
36bp repeat sequences.
• Inexpensive
• Fast
• Minimal DNA required
therefore samples do not
need to be cultured prior to
typing.
• Low resolution
• Can’t effectively
discriminate between
MTBC strains, particularly
Lineage 2 strains, all of
which lack spacers 1 – 34.
IS6110-Restriction
fragment length
polymorphism
(RFLP)
• IS6110 is a 1361bp IS3-family
mobile genetic element which can
be found in the varying frequency
and loci within the genome.
• The number of copies and the
site of IS6110 insertion are
detected via restriction digest
followed by blotting and labelling.
• Discriminatory power is
better than spoligotyping
and can resolve differences
between MTBC lineages.
• Can’t be used to accurately
type isolates with fewer
than 5 IS6110 bands.
• Requires large amounts of
good quality DNA.
Variable-number
tandem-repeat
typing (VNTR)
• Repetitive regions (40 – 100bp in
length) that are found at 41 loci
throughout the chromosome,
with varying number of repetitive
units. The regions are also known
as mycobacterial interspersed
repetitive units (MIRUs) and
therefore the technique can be
referred to as MIRU-VNTR.
• Polymorphism is detected via PCR
using primers specific for the
flanking regions of the repeats.
Can be performed on 15- or
24-loci, with 24-loci providing
better resolution.
• Better discriminatory
power than both RFLP and
spoligotyping.
• Minimal DNA required
therefore samples do not
need to be cultured prior to
typing.
• Automation requires a
sequencer and specialized
software.
Whole genome
sequencing
(WGS)
• The full genome sequence of the
isolate is determined. The most
common technique applied is
shotgun sequencing, generating
the sequence of short reads (25 –
450bp) after fragmentation of the
genome. Reads are then aligned
to a reference genome.
• Newer technologies, such as the
Nanopore and PacBio systems,
can sequence single molecules of
DNA to generate long reads [115].
These have not been widely
applied to MTBC due to cost and
availability of technology.
• Unrivalled resolution and
discriminatory power.
• Can provide lineage and
drug resistance
information.
• Can provide information
about specific SNP
differences at specific loci,
allowing investigation of
the functional implications
of genetic diversity.
• Short read sequencing data
can’t be used to determine
the sequence of repetitive
regions. This is major
disadvantage for Mtb given
that 10% of the genome
comprises repeat regions of
which the PE/PPE genes
being significant for the
proposed role in
host-pathogen interactions.
• Expensive
• Specialized software and
skilled personnel required
for data analysis.
• Standard techniques
require large amounts of
good quality DNA.
C© 2017 The Authors. European Journal of Immunology published by
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highly virulent in mice [18] and rabbits [19]. The HN878 strain,
and most other members of the lineage 2 strain family, produces a
phenolic glycolipid that dampens the proinflammatory response,
suggesting one mechanism for the increased virulence of these
strains [20]. In addition to transmission, associations between
specific MTBC lineages and the site of disease [21], clinical pre-
sentation, and the duration of disease [22] have been observed.
Evidence of significant differences in the transmission and
manifestations of disease of MTBC lineages worldwide (reviewed
in [23]), and variable evidence for host genetic polymorphism and
susceptibility to MTBC [24], suggests that genetic variation within
the MTBC may influence the host–pathogen interaction and out-
come of the infection. In this review, we specifically consider the
immunological consequences of MTBC lineage diversity on the
innate and adaptive response and discuss the potential transla-
tional implications of differences in the immunological response
to different MTBC strains.
The impact of MTBC lineage diversity on the
interaction with innate immune cell
receptors
Innate immune cell receptors are the first point of contact with
MTBC bacilli, and thus play an important role in downstream
immune response to MTBC. A wide range of pathogen recognition
receptors (PRRs) are involved in the initial interaction between
MTBC and host cells, including toll like receptors (TLRs), C-type
lectin receptors (CLRs), nod like receptors (NLRs) and scavenger
proteins [25, 26]. The cell wall structure of MTBC is complex,
including glycolipids and lipoproteins that are uniquely found
in pathogenic mycobacterial species and can vary between lin-
eages [27]. Together with secreted effector proteins, cell wall com-
ponents act as pathogen-associated molecular patterns (PAMPs)
that are recognized by host immune cells. Subtle differences in
cell wall components can impact the immune response [28] and
in addition to activating the immune response, many cell wall
components have immunomodulatory functions, which can mod-
ulate the immune response in favor of the bacterium [25]. In
the following sections we highlight experimental evidence that
demonstrates variation in PAMPs between MTBC lineages that
may influence interaction with PRRs.
C-type lectins
C-type lectins are one important class of receptor that func-
tion in innate immunity to TB. Alveolar macrophages highly
express Mannose-receptor (MR, CD206), while dendritic cell spe-
cific intercellular-adhesion-molecule-3 grabbing non-integrin (DC-
SIGN, CD209) is mostly highly expressed on dendritic cells (DC)
[29]. MTBC cell wall products such as lipoarabinomanan (LAM)
and mannosylated-lipoarabinomanan (Man-LAM) [29, 30] are
recognized by these receptors. Phagocytosis of MTBC via this path-
way leads to a reduced inflammatory response thereby presenting
an important route of entry from the perspective of the bacil-
lus [27, 30]. Structural variation in LAM between virulent and
attenuated Mtb laboratory strains results in lower macrophage
uptake in vitro of the attenuated Mtb H37Ra strain when com-
pared with more virulent H37Rv or Erdman strains [31]. Simi-
lar differences have been reported amongst clinical MTBC. A set
of lineage 2 isolates were identified as being deficient in uptake
by human monocyte-derived-macrophages (MDMs) in vitro when
compared with the Erdman Mtb strain (a lineage 4 strain) [32].
While links with diversity in lipid metabolizing genes were not
uncovered, biochemical characterization revealed that ManLAMs
in these strains where truncated and more highly branched, lead-
ing to reduced surface exposure and thus decreased engagement
with the MR [32].
Toll-like receptors (TLRS)
Toll-like receptors (TLRs) are another set of PRRs that are impor-
tant for sensing MTBC infection [25]. Differential recognition
of MTBC lineages may impact the response of phagocytes and
cytokine production [33]. Lipid and protein antigens from MTBC
can be recognized by TLR4 and human polymorphism in TLR9
is associated with TB susceptibility; however, due its affinity for
lipids, TLR2 is thought to be the dominant TLR for recognition of
MTBC [25, 34]. Lipid fractions from a lineage 2 isolate, the H37Rv
laboratory strain, andM. canettii have also been shown to differen-
tially affect TLR2 and TLR4 expression on macrophages. Human
MDMs produced higher levels of TNF-α and IL-10, and expressed
lower levels of TLR2 and TLR4 when stimulated with lipid frac-
tions from a lineage 2 strain when compared with H37Rv and
M. canettii [35]. In a subsequent study characterizing the ability
of lineage 2 strains to activate TLR2 and TLR4 receptors in mice,
Carmona et al. (2013) show that for most strains studied, cytokine
production by macrophages was induced via TLR2 activation [33].
However, a specific lineage 2 strain activated the TLR4 receptor on
bone marrow-derived macrophages, leading to production of IFN-
β, increased bacterial burden and lung pathology during the early
stages of mouse infection [33]. A study in mice demonstrated that
the lineage 2 HN878 Mtb strain induced lower levels of mRNA for
Th1 cytokines, TNF-α, IL-6, IL-12, and IFN-γ, and higher levels for
mRNA encoding type 1 IFNs, potentially explaining the increased
virulence of this strain in mice [18]. While this study did not
directly address the role of TLRs, preferential activation of TLR4
may partially explain this phenotype. However, Carmona et al.
(2013) also demonstrated that activation of TLR4 was not specific
to lineage 2 strains, with the Mtb Haarlem sub lineage strain, a
member of lineage 4, also able to activate TLR4 with concomittant
production of IFN-β [33]. In addition, the production of IL-17 via
a TLR2-dependent pathway was shown to be protective for mice
infected with HN878 but not H37Rv [36]. These studies demon-
strate that immunological differences associated with MTBC strain
variation are likely to arise from the interaction between multiple
factors and immune receptors.
An interaction between host and bacterial genotype has been
observed with respect to TLRs and susceptibility to disseminated
TB disease [37] (Table 2). In particular, lineage 2 isolates were
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Table 2. Studies describing the impact of both MTBC genotype and host genotype on immunological outcomes of TB infection
Geographic
location
Variation in immune
component
Methods used to genotype MTBC
strains
Key finding Reference
Ghana 5-lipoxygenase (ALOX5) • Clinical MTBC strains were
genotyped by spoligotyping
and IS6110 fingerprinting
• Heterozygous “5/non 5” promoter
mutation that results in lower levels
of 5-LO was associated with TB
susceptibility regardless of MTBC
lineage.
• The exonic variant G760A in males
was associated with TB caused by
infection by lineage 6 strains.
[96]
Ghana Autophagy related
human
immunity-related
GTPase M (IRGM)
• Clinical MTBC strains that
were genotyped by
spoligotyping, MIRU-VNTR,
IS6110 fingerprinting and
pks1-15 region typing.
• The IRGM genotype –261TT was
associated with relative protection
against TB caused by Mtb lineage 4
but not M. africanum.
• Stratification of MTBC strains
showed that protection was specific
against TB caused by lineage 4
strains with a disrupted pks1-15
gene.
[116]
Ghana Mannose Binding Lectin
(MBL)
• Clinical MTBC strains
genotyped using LSP typing,
IS6110 fingerprinting and
typing of the pks1-15.
• MBL2 G57E variant was associated
with protection against TB caused by
M. africanum but not Mtb sensu
stricto.
[42]
Ghana Macrophage
Chemoattractant
Protein 1 (MCP-1)
• Clinical MTBC strains
genotyped
IS6110 fingerprinting,
spoligotyping and MIRU-VNTR.
• MCP-1 genotypes variants were
associated with resistance to
tuberculosis and this was not
affected by MTBC lineage
differences.
[117, 118]
The
Gambia/
Guinea-
Bissua
Epiregulin (EREG) and
V-ATPase (TCIRG1)
• Clinical MTBC strains
genotyed using spoligotyping
• Marginal association between
rs11228127 in TCIRG1 and patients
infected with M. africanum in The
Gambia.
[119]
South
Africa
HLA class I • Clinical MTBC strains
genotyped by spoligotyping
and IS6110 fingerprinting.
• Associations between several
lineages and specific HLA haplotypes
e.g. A*03 was associated with infection
by lineage 4 strains.
[120]
Vietnam TLR2 and TIRAP • Clinical MTBC strains
genotyped by
IS6110 fingerprinting, large
sequence polymorphsm and
MIRU-VNTRs.
• C allele of TLR-2 T597C was
associated with TB disease caused by
lineage 2 MTBC strains.
[37]
Vietnam Macrophage receptor
with collagenous
structure (MARCO)
• Clinical MTBC genotyping by
IS6110 fingerprinting, MIRU
and pks1-15 region typing.
• Two heterozygous (AG) genotypes
(rs2278589 and rs6751745) were
associated with impaired
phagocytosis of MTBC and increased
susceptibility to lineage 2 strains but
not lineage 4 and lineage 3 Mtb
strains.
[121]
Indonesia SLC11A1 gene (also
known as “NRAMP1”)
• Clinical MTBC strains
genotyped by spoligotyping.
• Lineage 2 strains were significantly
associated with the G allele and the
GG phenotype of the D543N
polymorphism compared to
non-lineage 2 strains.
[122]
Russia CD209 (DC-SIGN) • Clinical MTBC strains
genotyped by spoligotyping
and MIRU-VNTR.
• Strong association between the G
allele of CD209 -336A/G and
increased mortality from TB caused
by lineage 2 strains.
[123]
C© 2017 The Authors. European Journal of Immunology published by
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more likely to cause meningeal tuberculosis in individuals with
the C allele of the T597C polymorphism in TLR2. While the impli-
cations for this allele on TLR2 function is not known, this study
suggests an important interaction between TLR2 polymorphism
and bacterial genotype in TB susceptibility [37].
Mannose binding lectin (MBL)
Mannose Binding Lectin (MBL), a member of the collectin family,
acts as an opsonin by binding pathogen cell surface carbohydrates
[38, 39]. While some studies have reported that patients with high
serum MBL are more susceptible to TB (reviewed in [40]), oth-
ers suggest the opposite (reviewed in [41]). A study conducted in
Ghana suggests that diversity between MTBC lineages might par-
tially explain this difference. The study showed that a relatively
high proportion of the population studied had an MBL polymor-
phism [42] that results in lower serum availability of functional
MBL by distrupting formation of oligomers [43]. The polymor-
phism was associated with a protective effect against infection
with strains of the M. africanum lineage but not strains from Mtb
sensu stricto lineages. Furthermore, M. africanum strains were
better able bind to wild-type MBL than the H37Rv Mtb strain in
vitro, suggesting that M. africanum uses this receptor as an entry
ligand thereby promoting infection. This potentially explains why
polymorphisms in MBL are protective against M. africanum but
not Mtb sensu stricto [42].
These studies highlight the need to take human genetic vari-
ation into account when considering differential immunological
outcomes associated with MTBC strain variation. Studies inves-
tigating association between polymorphism and human suscep-
tibility to TB disease have yielded discrepent results (reviewed
in [24, 44]), and relatively few studies have taken MTBC genetic
diversity into account (highlighted in Table 2). Discrepant associ-
ations between polymorphism in host and TB susceptibility might
be partially explained by MTBC variation. Matching bacterial
and host genotypes presents a challenge to the field. To pro-
duce generalizable insights going forward, these studies should
involve more than one population and be large enough to be well
powered.
The response of innate immune cells to
diverse MTBC lineages
The early response to MTBC infection is characterized by a sys-
temic inflammatory response that is mediated by macrophages,
neutrophils, DC, and innate T cells [26, 34]. The observation that
a proportion of people heavily exposed to MTBC do not develop
evidence of sensitization suggests that the innate immune system
may completely clear MTBC before infection is established, high-
lighting the importance of these mechanisms [45]. The innate
immune response also activates and augments adaptive responses
to MTBC infection. MTBC has developed various mechanisms to
interfere with effective innate immune function and variation in
the capability of various MTBC strains and lineages to do this may
significantly influence the outcome of MTBC infection.
Macrophages
Monocyte andmacrophage cell populations have beenwidely used
to study differences in virulence between MTBC lineages. In the
following section we highlight some studies that have investigated
the macrophage and macrophage-like cell response to different
MTBC lineages.
A study comparing the capacity of MTBC strains, to grow and
stimulate cytokine production in primary human monocytes and
THP-1 macrophage-like cells, that were either transmitted within
households or not transmitted within households suggested that
transmitted MTBC isolates grew more rapidly than strains that
were not transmitted, in both kinds of cells [46]. In addition to
growth patterns, cytokine production by monocytes infected with
different MTBC isolates has been widely studied. Using represen-
tative strains for each lineage, Portevin et al. (2011) showed that
modern strains (lineage 2, 3, and 4) of MTBC elicited a lower early
inflammatory response, as characterized by cytokine production
in human peripheral blood MDMs than ancient MTBC strains (lin-
eage 1, 5, and 6) [47]. This suggests that modern MTBC strains
have adapted to cause more rapid disease progression and there-
fore transmission [47]. In support of this, mice infected with more
evolutionary modern sublineages of lineage 2 MTBC strains, iso-
lated in Brazil and Mozambique, had greater lung pathology and
lower survival than mice infected with lineage 2 strains that were
more evolutionarily ancient [48]. MTBC lineages seem to exhibit
a lineage-specific transcriptional pattern in macrophages [49];
however, within the modern MTBC group, sublineage-specific
patterns of cytokine production by macrophages have also been
observed [50] suggesting that significant intra-lineage variation
also occurs with regards to transcriptional patterns.
Differences in monocyte activation have been shown to
be partially responsible for the differences in virulence of
the well-known CDC1551 and HN878 outbreak MTBC strains
[51]. In particular, human peripheral blood mononuclear cells
(PBMC) infected with CDC1551 produced higher levels of pro-
inflammatory cytokines, IL-1α/β; IL-1α, and MIP3-α, indicative
of Th1 type immunity and immune protection. In contrast,
HN878 stimulated high levels of IL-4 and IL-13, which are
characteristic of the Th2 type immune response [51]. A study
published around the same time demonstrated that production
of pro-inflammatory cytokines in murine bone-marrow-derived
macrophages was inhibited by a phenolic glycolipid produced
by HN878. Deletion of pks1-15, the genes encoding the polyke-
tide synthase enzymes that produce this lipid, led to abroga-
tion of this phenotype directly linking a mycobacterial genetic
determinant to an immunological phenotype [20]. A lineage 3
strain responsible for a large TB outbreak in Leicster, UK, stim-
ulated higher levels of the anti-inflammatory cytokine IL-10 and
lower pro-inflammatory IL-12p40 from human MDMs, suggest-
ing phagocyte deactivation [52]. By systematically complementing
C© 2017 The Authors. European Journal of Immunology published by
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deletions specific to this MTBC strain, the authors showed that the
phenotypic reaction in macrophages was related to the specific
deletion of Rv1519. However, the precise function of this gene in
MTBC is unknown [52].
Neutrophils
Neutrophils are the first innate cells to migrate to the site of infec-
tion and represent the most highly infected phagocytes in the
airways of active pulmonary TB patients [53]. Moreover, a whole
blood neutrophil driven type I interferon transcriptional profile
characterizes active from latent TB [54]. Studies have shown that
TNF-α-activated neutrophils can phagocytose and kill MTBC via
α-defensins and proteases rather than ROI and RNI [55, 56].
Outbreaks of multidrug resistant (MDR)-Mtb caused by strains
belonging to the Harlem and LAM family of lineage 4 were
shown to induce a differential respiratory burst from human neu-
trophils [57]. In particular, apoptosis of neutrophils was more
strongly induced by strains of the LAM family, leading to con-
comitant production of ROI. By contrast the Haarlem family strain,
which has been responsible for an ongoing MDR-TB outbreak in
Argentina, induced significantly less neutrophil apoptosis, suggest-
ing that this ability might be one of the reasons for its success [58].
This phenotype may be due to differences in the strucutre of
α-glucans present on the cell wall of the Haarlem strain, which
promotes non-apoptotic neutrophil pathways, allowing the bacte-
ria to sequester and replicate [57].
Dendritic cells
DC make up a large proportion of MTBC-infected cells, and play
an important role in the response to MTBC by transporting antigen
to the lymph nodes where it is presented to and activates na¨ıve
T cells [26, 45]. The function of DC can be inhibited by MTBC and
murine bone-marrow-derived DC stimulated with soluble extracts
from the HN878 lineage 2 Mtb strain expressed lower levels of
surface MHC class II molecules, and led to less activation of CD4+
T cells than less virulent H37Rv and BCG strains [59]. In a separate
study, exposure of human monocyte-derived DCs to clinical Mtb
isolates from India, whose genotypes were not defined, resulted in
reduced migration of DCs towards a chemokine ligand important
to guide DCs to lymphoid tissue, CCL21, compared to LPS stimu-
lation of DCs [60]. A study profiling a relatively large number of
clinical Mtb isolates using semi-global protein arrays and ELISA-
arrays showed that human monocyte-derived DCs infected with
lineage 2 Mtb isolates generally produced lower levels of TNF,
IL-6 and IL-10 than the H37Rv strain, suggesting that this might
be a mechanism of increased virulence of these strains [61]. Con-
trasting results were found in a separate study investigating the
virulence of different MTBC strains isolated from TB meningitis
patients. In this study, there was no difference in cytokine produc-
tion bymurine bone-marrow-derived DC in vitro; however, lineage
2 and 3 isolates displayed higher virulence in mice than lineage
4 strains, with more rapid growth and increased dissemination to
the blood and lung pathology [62].
Variation in the adaptive immune response
to MTBC lineages
There is a considerable delay in the onset of the adaptive immune
response to MTBC, which primarily consists of a T helper 1 (Th1)
T cell response. CD4+ T cells differentiate into Th1 cells producing
IFN-γ, TNF-α andGM-CSF to activate infectedmacrophages. These
macrophages in turn restrict intracellular MTBC by initiating the
formation of RNI and ROI, and by autophagy [63]. Th1 cells also
produce IL-2 that promotes proliferation and increased cytokine
synthesis by T cells and NK cells and LT-α (lymphotoxin-α), which
is necessary for recruitment and activation of neutrophils. CD8+
T cells also have a role in protection against MTBC. Production of
granulysin and serine esterase containing granzymes may directly
kill MTBC [64], while the production of cytokines such as IFN-γ
and TNF-α activates phagocytes, and the production of IL-2 pro-
motes the proliferation of NK and T cells, indirectly contribut-
ing to the control of MTBC [65]. While the T cell response has
been widely studied, less is known about variation in the B-cell
response in TB. However, recent work characterizing antibodies
from humans with active and latent TB suggests that B cells may
play a significant role in protection against TB [66, 67]. Ulti-
mately adaptive immunity results in the formation of a granu-
loma comprised of uninfected macrophages that confine infected
macrophages, epithelioid cells and neutrophils. This barrier is then
surrounded by T and B cells, thus providing a physical barrier to
contain MTBC [45].
T-cell-mediated immunity
Characterization of the adaptive response to whole cell MTBC has
revealed differences in the T cell response to different lineages.
A low dose aerosol guinea pig model of infection was applied to
examine differences in virulence of a set of lineage 2 MTBC iso-
lates selected for their differences in transmission [68]. All strains
elicited an appreciable Th1 response, with increased mRNA levels
for IFN-γ, IL-12p40, and TNF-α in the lungs, and the presence of
activated T cells by day 30 of the infection. However, two strains,
which caused a significantly greater number of secondary cases,
elicited higher levels of Foxp3 and TGF-β mRNA in the lungs at
day 60, coinciding with a drop in the number of activated CD4+
T cells, suggesting expansion of regulatory T cells [68]. A study
applied a mouse model to extenstively characterize the virulence
and T cell response to the K strain, a lineage 2 Mtb isolate respon-
sible for a TB outbreak in a Korean school [69]. The K strain was
more virulent in mouse lungs, with rapid growth and more exten-
sive pathology, when compared the H37Rv or H37Ra laboratory
strains. In addition to differences in the innate response in the
mouse lung, the study demonstrated differences in the kinetics of
T cell subtypes in animals infected with different MTBC strains. In
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the lungs of mice infected with all strains, Th1 T-bet expressing
CD4+ T cells had accumulated by 14 days, however, at 28 days,
these cells began to decrease in the lungs of mice infected with
the K strain compared to the H37Rv and H37Ra laboratory strains.
Moreover, CD4+ T cells expressing RORγt, thought to represent a
Th17 subset, were not present in the lungs of mice infected with
the K strain while they were present in appreciable numbers in
mice infected with laboratory strains, H37Rv and H37Ra. Simi-
larly to the guinea pig study discussed above, higher numbers of
CD4+CD25+Foxp3+CD223+IL-10+ T-regulatory (Treg) cells were
observed in K Mtb strain infected mice when compared with
H37Rv or H37Ra strains [69]. In a separate study, in mice infected
with HN878, higher numbers of Treg cells were observed within
21 days of infection when compared with H37Rv, suggesting a
potential contribution of this cell type to the virulence of this
strain [70]. While the genetic determinants driving the mecha-
nisms for these observations are unclear, one possible explanation
is that some Mtb strains express yet to be discovered antigens that
specifically stimulate the expansion of regulatory T cells [69].
Epitope variation in MTBC
Unlike many bacterial pathogens, several genomics studies have
revealed that MTBC T cell epitopes appear to be genetically con-
served [10, 71]. However, almost all of the WGS data generated
thus far utilizes short-read sequencing platforms, which are not
able to efficiently determine sequence in highly repetitive genetic
regions, some of which are antigenic [72]. One of themost variable
regions of theMTBC genome – the PE/PPE gene family – comprises
highly repetitive sequences that are routinely filtered out of WGS
datasets. Several of the PE proteins have been shown to elicit both
cellular and humoral responses in a wide range of models stud-
ied [73]. This observation has led to the hypothesis that these
regions may be a source of antigenic variation as yet undetected
by WGS. However, a study characterizing the immunogenicity of
a relatively large set of PE proteins in cattle infected with M.
bovis, or PBMC from humans infected with Mtb, revealed that
both the proportion of responders and the breadth of response,
as measured by IFN-γ production, were positively correlated with
sequence conservation [74]. The study did not characterize the
highly variable PE PGRS subfamily of these genes; however, com-
putational prediction of epitopes in the PE PGRS subfamily indi-
cated that epitope encoding regions mostly occurred in conserved
PE domain of these proteins [71]. Furthermore, the impact of
non-synonymous SNPs occurring in these regions in 94 clinical
Mtb isolates was found to be negligible for predicted HLA class I
and II binding, and epitope prediction [71]. While these findings
suggest that epitopes are conserved in MTBC even in genomic
regions thought to be variable, a small subset of MTBC epitopes
that are highly variable were recently uncovered by comparative
genomics [75]. The immunogenicity of a selection of these epi-
topes was determined by measuring IFN-γ responses in whole
blood from HIV-uninfected TB patients in the Gambia, reveal-
ing differential responses to ancestral and variant epitope pep-
tides [75]. These findings have important potentially implications
for vaccine development, discussed in more detail below.
Translational implications of MTBC lineage
associated variation in host immunity
Implications of MTBC lineage variation for vaccine
development
The translational implications of MTBC lineage variation is per-
haps most apparent for the design of effective new TB vaccines.
Escape from BCG vaccination is one of the factors proposed to
have driven thewide geographic distribution of the lineage 2 geno-
type [76, 77]. A recent reconstruction of the evolutionary history
of Mtb lineage 2 strains, by genetic characterization of more than
one thousand isolates, suggests that BCG vaccination had minimal
impact on the population size of lineage 2, suggesting vaccination
was insufficient to prevent lineage 2 dissemination [12]. To deter-
mine whether this is specific to the lineage 2 genotype or due to
general variability in BCG efficacy would require similar charac-
terization of MTBC lineages. Data from BALB/c mice and a rabbit
model suggest that BCG vaccination provides lower levels of pro-
tection against challenge with lineage 2 isolates [78, 79]; how-
ever, these findings were not reproduced in C57BL/6 mice [80].
A subsequent study conducted in C57BL/6 mice and guinea pigs
suggested that BCG conferred acceptable levels of protection to
lineage 2 strains isolated in South Africa, but not against those
isolated in the USA [81]. The authors suggest that variable BCG
protection is a function of strain fitness, rather than lineage diver-
sity; however, in all of these studies only a few isolates of lineage
2 strain were investigated [81].
In terms of new vaccines, the recombinant BCG candidate
(VPM1002) expressing listeriolysin but defective in urease pro-
duction, was shown to confer better protection than standard
BCG in BALB/c mice, hypothesized as a result of increased anti-
gen translocation into the cytoplasm of infected macrophages and
resultant antigen cross-priming [82]. Moreover, this vaccine con-
ferred a similar level of protection against a lineage 2 strain as
H37Rv [82]. VPM1002 is currently in Phase II trials as a BCG
replacement candidate vaccine in HIV-infected infants, and is pro-
posed for Phase III efficacy trials [83].
As previously discussed, several comparative genomics studies
have shown that in MTBC, unlike other bacteria such as Strep-
tococcus pneumoniae, T cell epitopes are evolutionarily conserved
[10, 75]. While the biological consequences are not completely
understood, these findings imply that these epitopes are conserved
because they fulfill an important biological role, and that immune
recognition of MTBC may favor the pathogen [10, 84]. One of
the proteins in a polypeptide candidate TB vaccine, M72/AS0E1,
which recently yielded acceptable safety results in a phase II
trial [85], contains a sequence from a PE protein discussed in
previous sections. High sequence variability among MTBC clini-
cal isolates has been observed in these specific proteins [86, 87].
Although the direct effects of the observed sequence variability on
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
440 Leopold D. Tientcheu et al. Eur. J. Immunol. 2017. 47: 432–445
the proteins’ immunogenicity has not yet been established, these
findings may warrant further investigation.
Impact of MTBC lineage diversity on TB diagnostics
Currently available tools for detection of MTBC infection rely
on immunological sensitization and thus could theoretically be
influenced by MTBC lineage associated immunological variation.
The TST has traditionally been used detect latent TB infection
(LTBI). The test, which requires subcutaneous injection of puri-
fied protein derivative (PPD) cannot differentiate MTBC infec-
tion from BCG vaccination or exposure to environmental non-
tuberculous mycobacteria (NTMs), and thus may yield false
positive results [88]. IFN-γ release assays (IGRA) are a set of
newer generation tests that measure in vitro IFN-γ production
in whole blood or PBMC in response to MTBC antigen stimula-
tion, such as CFP10 and ESAT-6 (and p38-55 of Rv2654c) [89].
Although IGRA are still unable to discriminate active from latent
infection, the absence of the CFP10 and ESAT-6 in BCG and most
NTMs confers on IGRA increased specificity to detect MTBC sensi-
tization [89]. However, the attenuated T cell response to ESAT-6
stimulation inM. africanum infected individuals has been shown to
affect the interpretation of IGRA results [90]. In addition, a num-
ber of studies have reported that activated T cell markers [91] and
soluble cytokines [92] can be used as reliable biomarker for mon-
itoring the anti-TB treatment response. It has been shown that
the production of 27 proinflammatory and regulatory cytokines
in response to ESAT-6/CFP-10 stimulation was not significantly
different between M. africanum and Mtb-infected patients pre-
treatment. However, the kinetics of production of these cytokines
following treatment was significantly different between the two
groups, with IFN-γ and GM-CSF significantly higher in Mtb com-
pared with M. africanum infected patients post-treatment [93].
These studies reveal that the interpretation of cytokine production-
based diagnostic tests for monitoring anti-TB treatment response
may need to account for MTBC lineage variation in West Africa
where M. africanum is prevalent.
The influence of MTBC lineage diversity on novel
host-directed therapies
MTBC lineage diversity may also constitute an important factor
to consider in the development of host-directed therapies (HDT).
Some HDT aim to augment the host defense against TB by mod-
ulating host pathways involved in the elimination of MTBC [94].
Due to both host and MTBC genetic variation, the efficacy of an
HDT targeting a specific pathway might differ in specific popula-
tions. For example, a combination of zileuton and prostaglandin
E2 (PGE2) as an HDT, which abrogates the detrimental type 1
interferon response and boosts eicosanoid levels, may find utility
in TB therapy [95]. The exonic g.760A allele in ALOX5, a keymedi-
ator of the type 1 IFN response to TB infection, is associated with
protection against TB caused by M. africanum strains but not Mtb
senstu stricto [96] (Table 2). While the functional implications of
this variant are not known, the association could influence indi-
vidual responses to the aforementioned HDT. In another example,
the virulent lineage 2 HN878 isolate was shown to stimulate a
high level of type 1 Interferon signaling in mice [18, 97], suggest-
ing that higher levels of HDT that modulate eicosanoids might be
required to be effective against infection with lineage 2 strains, or
conversely that the HDT may actually be more effective in persons
infected with lineage 2 strains.
The impact of HIV co-infection on
immunological outcomes associated with
different MTBC lineages
Due to dysregulated host immunity, it has been suggested that
HIV-1 co-infection may facilitate the survival of less “fit” MTBC
lineages within a population [2]. It has been observed that TB
is not transmitted efficiently from HIV-1 co-infected individuals,
thus transmission predominantly occurs from HIV-1 uninfected
individuals to HIV-1 co-infected individuals [98, 99]. A recent
study modelling the impact of HIV-1 on a large MDR outbreak in
South America found no evidence of association between HIV-1
and the mutation rate of Mtb, or MDR-TB transmission [100].
MTBC creates an inflammatory milieu that exacerbates HIV-1
infection and increases viral replication [26]. Activation of nuclear
factor (NF)-κβ pathway and positive transcription elongation fac-
tor (P-TEFβ), loss of CCAAT/enhancer-binding protein and other
chemokine and cytokine dependent pathways underlie this phe-
nomenon [26]. Clinical isolates of MTBC have been shown to
differentially affect the replication of HIV-1 in PBMC [101]. For
example, the lineage 4 CDC1551 strain induced higher levels
of viral replication in human PBMCs than the lineage 2 HN878
strain [101]. The HN878 strain contains an intact pks1-15 gene
cluster resulting in production of a virulence associated pheno-
lic glycolipid [20]. Viral replication in PBMC co-infected with a
mutant HN878 pks1-15 deletion strain, which no longer produces
the phenolic glycolipid, was similar to levels observed in PBMC
co-infected with the CDC1551 strain. This suggests that strain
specific effects on HIV-1 replication are associated with cell wall
components of MTBC [101]. MTBC dependent enhancement of
HIV-1 replication was subsequently shown to be a result of direct
binding of transcription factor nuclear factor of activated T cells 5
(NFAT5) to the HIV-1 LTR promoter [102]. NFAT5 expression was
induced in macrophages after MTBC infection in THP-1 cells in a
TLR2 dependent manner. While the authors did not examine the
influence impact of MTBC strain variation in this study [102], the
discussion above highlights the differential effects MTBC might
have on TLRs. Together these findings suggest that MTBC strain
variation may have important implications for of HIV-1 replica-
tion, and disease progression during HIV/TB co-infection [102].
Conclusion
The studies discussed above indicate that genetic diversity within
the MTBC can influence the host response to infection and during
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 432–445 HIGHLIGHTS 441
TB disease. However, the use of in vitro systems and animal mod-
els that do not completely recapitulate human TBmakes it difficult
to assess whether immunological variation associated with MTBC
genetic diversity appreciably impacts clinical outcome, or whether
TB control approaches should be tailored according to the infect-
ing MTBC strain. The use of techniques such 2-deoxy-2-[18F]-
fluoro-D-glucose (FDG) positron emission tomography/computed
tomography (PET/CT) [103] and transcriptional profiling [54]
during TB infection have recently provided important insights
into pathophysiology within the human host and could be applied
to investigate the impact of MTBC strain diversity on clinical
outcome.
In addition to technical considerations associated with the
immunological readout, many studies have characterized only a
few representatives of a lineage, in many cases those that have
been associated with well-known outbreaks. Significant intra-
lineage diversity exists [12, 13] making extrapolation of phe-
notypes phenotypes associated with a few representatives to an
entire lineage difficult. Moreover, as previously discussed, almost
all MTBC WGS data have thus far been generated via short read
sequencing techniques. Sequence in highly repetitive regions can-
not reliably be determined using these techniques and are usually
removed from downstream analysis [72]. Short read data are also
not useful for detecting genomic changes such as deletions and
duplications, particularly those that span larger regions of the
genome. These changes in genetic architecture, as well as epige-
netic changes such as methylation patterns, may have important
implications for MTBC physiology and associated host–pathogen
interactions [104]. Newer technologies, such as the PacBio sys-
tem and hybrid sequencing strategies, which combine short-read
sequencing with single molecule sequencing [105], will provide
the opportunity to investigate these genomic alterations and their
associated immunological phenotypes.
In terms of childhood TB, studies suggest that associations
between particular MTBC genotypes and TB in children is likely
to reflect ongoing transmission from adults [106–108]. However,
variation in immunological outcomes due to MTBC genetic diver-
sity in childhood TB specifically has not been extensively investi-
gated. Given the immunobiology of TB disease in children is dis-
tinct from that of adults and varies with age [109], this presents
an important area for further research.
Finally, definitively establishing genotype–phenotype relation-
ships may benefit from allelic exchange type experiments that
facilitate an understanding of cause and effect between a polymor-
phism and a particular phenotype [110]. However, genetic manip-
ulation of clinical isolates is likely to be challenging and complex
phenotypes may result from epistatic interactions between multi-
ple SNPs.
The aforementioned caveats notwithstanding, the studies dis-
cussed here have uncovered important variation in innate and
adaptive immune responses to different MTBC strains, that war-
rants further investigation. The use of new immunological, clin-
ical, and genomics techniques provides the opportunity to pur-
sue and throw greater light on their significant in tuberculosis
response.
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